[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100581832":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":28,"locations":24,"responsibleParty":37,"collaborators":41,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":46,"sex":52,"minAge":53,"maxAge":24,"enrollmentInfo":54,"targetDuration":24,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":68,"whyStopped":24,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":24},{"fullName":5,"class":6},"Brigham and Women's Hospital","OTHER",[8,13],{"label":9,"type":10,"description":9,"interventionNames":11},"Colchicine","EXPERIMENTAL",[12],"Drug: Colchicine Pill",{"label":14,"type":15,"description":14,"interventionNames":16},"Placebo","PLACEBO_COMPARATOR",[17],"Drug: Placebo",[19,25],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Colchicine Pill","Colchicine 0.6mg tab, overencapsulated to match placebo capsule, taken by mouth once daily",[9],null,{"type":20,"name":14,"description":26,"armGroupLabels":27,"otherNames":24},"Placebo capsule, taken by mouth once daily",[14],[29,34],{"name":30,"role":31,"phone":32,"phoneExt":24,"email":33},"Jacklyn Stratton, Senior Project Manager","CONTACT","617-525-8784","jstratton1@bwh.harvard.edu",{"name":35,"role":31,"phone":24,"phoneExt":24,"email":36},"Sara Tedeschi, MD, MPH","stedeschi1@bwh.harvard.edu",{"type":38,"investigatorFullName":39,"investigatorTitle":40,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"PRINCIPAL_INVESTIGATOR","Sara Tedeschi, M.D., M.P.H.","Assistant Professor of Medicine",[42],{"name":43,"class":6},"Rheumatology Research Foundation","100581832","phase-2-colchicine-to-reduce-your-symptoms-and-lower-levels-of-inflammation-zeroing-in-on-effective-cppd-disease-treatment-100581832",false,"NCT06855433","Colchicine to Reduce Your SympToms And Lower Levels of Inflammation, Zeroing in on Effective CPPD Disease Treatment","A Randomized, Double-Blind, Multi-Site Placebo Controlled Trial of Colchicine in Calcium Pyrophosphate Deposition Disease","CRYSTALLIZE","Inclusion Criteria:\n\n* Provide written informed consent\n* Fulfill ACR\u002FEULAR 2023 CPPD classification criteria\n* Acute or chronic joint inflammation in the past 3 months, not attributable to another condition\n* Pain visual analog scale (pain VAS) \\>=30 at screening\n\nExclusion Criteria:\n\n* age \\\u003C40 years\n* chronic diarrhea\n* gout, rheumatoid arthritis, or psoriatic arthritis\n* cirrhosis\n* ongoing use of colchicine and unwilling to undergo a 30-day wash-out period (note: patients using colchicine at screening can enroll if they agree to a 30-day wash-out before randomization)\n* pregnant or breast-feeding\n* use of methotrexate, hydroxychloroquine, or anakinra in the past month\n* use of oral glucocorticoid in the past week\n* use of strong CYP3A4 inhibitors per FDA package insert for colchicine\n* use of P-glycoprotein inhibitors per FDA package insert for colchicine\n* known allergy to colchicine\n\nScreening labs with any of the following:\n\n* hemoglobin \\\u003C 11.5 g\u002FdL\n* WBC \\\u003C3 x 10\\^9\u002FL\n* platelets \\\u003C110 x10\\^9\u002FL\n* creatinine clearance (CrCl) \\\u003C30 mL\u002Fmin\n* ALT or AST \\>3x upper limit of normal (ULN)","ALL","40 Years",{"count":55,"type":56},150,"ESTIMATED","INTERVENTIONAL",[59],"PHASE2","The goal of this clinical trial is to learn if colchicine reduces levels of proteins indicating inflammation in the blood in individuals with calcium pyrophosphate deposition (CPPD) disease. The trial will also test the effect of colchicine on joint symptoms in CPPD disease. The main questions it aims to answer are:\n\n* Does colchicine reduce the level of interleukin 18 (IL-18) in the blood of individuals with CPPD disease?\n* Does colchicine reduce pain scores in individuals with CPPD disease?\n\nResearchers will compare colchicine once daily to a placebo (a look-alike pill that contains no drug) to see if colchicine works to treat CPPD disease.\n\nParticipants will:\n\n* Take colchicine or a placebo every day for 6 months\n* Visit the clinic 3 times in 6 months for joint examinations, surveys, and blood tests. Each visit will last 2-3 hours.\n* Speak on the telephone with researchers for about 4 times over 6 months. Each phone call will last about 5 minutes.",[62],"CPPD - Calcium Pyrophosphate Deposition Disease",[64,65,66,67],"colchicine","CPPD disease","calcium pyrophosphate","pseudogout","NOT_YET_RECRUITING","2026-05-27",{"date":71,"type":72},"2026-05-29","ACTUAL",{"date":74,"type":56},"2026-07-01",{"date":76,"type":56},"2030-09-30",{"name":5,"class":6}]